['melanoma and brain metastases']
['dabrafenib', 'trametinib']

        Inclusion Criteria:

          -  ECOG Performance Status range of 0-2

          -  Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.

          -  May be systemic naïve or received up to two previous systemic treatment regimens for
             metastatic melanoma.

          -  Must be able to undergo MRI and have at least one measurable intracranial lesion for
             which specific criteria have to be met.

        Exclusion Criteria:

          -  Prior treatment with any BRAF inhibitor or any mitogen-activated protein/extracellular
             signal-regulated kinase inhibitor.

          -  Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without
             delayed toxicity within treatment specific timeframe.

          -  Treatment with stereotactic radiosurgery or treatment with whole-brain radiation
             within treatment specific timeframe.

          -  Any presence of leptomeningeal disease or any parenchymal brain metastasis

          -  History of another malignancy, some exceptions may apply.

          -  A history or evidence of cardiovascular risk- specific criteria have to be met

          -  A history or current evidence/risk of retinal vein occlusion or retinal pigment
             epithelial detachment - specific criteria have to be met.
      